Drugs / HW211026
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07318675 | Dec 2025 → Mar 2026 overdue | actinic keratosis | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07513454 | Jul → Dec 2026 expected | actinic keratosis | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HW211026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07318675 ↗ |
| Route | Topical | “topical administrations” NCT07318675 ↗ |